CIA
ACAD icon

CSat Investment Advisory’s Acadia Pharmaceuticals ACAD Stock Holding History

CSat Investment Advisory’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-694
Closed -$29K – 521
2020
Q3 		$29K Buy
694
+88
+15% +$3.8K ﹤0.01% 767
2020
Q2 		$29K Buy
+606
New +$29.1K ﹤0.01% 749

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CSat Investment Advisory's ACAD Position: Q4 2020 in Review

CSat Investment Advisory sold out of Acadia Pharmaceuticals (ACAD) in Q4 2020, closing a stake of 694 shares — an estimated $29K sold.

CSat Investment Advisory first reported a position in ACAD in Q2 2020 and held it in 2 quarters. The position peaked at $29K in Q3 2020. 308 funds tracked by Wall St. Rank hold ACAD as of Q4 2020.

  • CSat Investment Advisory reported no remaining Acadia Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • CSat Investment Advisory sold 694 Acadia Pharmaceuticals shares in Q4 2020, an estimated $29K.
  • CSat Investment Advisory first reported a position in Acadia Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • CSat Investment Advisory's Acadia Pharmaceuticals position peaked at $29K in Q3 2020.
  • 308 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2020.

Based on CSat Investment Advisory's 13F filing for Q4 2020, filed 12 Feb 2021.